Li Zhang

发表

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Yan Sun, Li Zhang, John V Heymach, 2010, The Lancet. Oncology.

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers

Jianxing He, Baorui Liu, Jian-hua Chang, 2022, The oncologist.

Efficacy and safety of immune checkpoint inhibitor consolidation after chemoradiation in patients of Asian ethnicity with unresectable stage III non‐small cell lung cancer: Chinese multicenter report and literature review

Wei Jiang, Jun Liang, Jianyang Wang, 2020, Thoracic cancer.

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

Dong Wang, Yuankai Shi, S. Qin, 2015, PloS one.

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

G. Zhu, H. Bai, C. Xue, 2012, OncoTargets and therapy.

Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

W. Feng, Yanda Lu, Zhenzhong Su, 2022, Cancer communications.

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Y. Luo, Q. Xiu, Yan Zhang, 2013, Annals of Oncology.

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

J. Milanowski, J. Aerts, R. Ramlau, 2023, Journal of Clinical Oncology.

Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial

Ying Cheng, Yanqiu Zhao, N. Yang, 2023, Signal transduction and targeted therapy.

Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

G. Zhu, H. Bai, C. Xue, 2012, OncoTargets and therapy.

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Y. Luo, Q. Xiu, Shucai Zhang, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

R. Greil, J. Milanowski, J. Aerts, 2023, The Lancet. Oncology.